BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Ipsen’s Onivyde Flops in Late-Stage Small Cell Lung Cancer Trial

  Ipsen said that Onivyde did not show greater benefit than topotecan used in patients with SCLC who have progressed on or after platinum-based first-line therapy treatment.

  August 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Anticipating Fragmented Booster Market, Moderna Prioritizes New Product Launches

  While Moderna’s sole marketable program is its COVID-19 vaccine, CEO Stéphane Bancel said the company is “actively working to prepare...new product launches to help patients and drive growth.”

  August 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Merck’s Keytruda Takes Another Hit with Phase III Prostate Cancer Fail

  Although no new safety concerns were observed, Merck’s Keytruda did not demonstrate significant improvements based on the pre-specified statistical plan.

  August 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  New Genetic Target, CIDEB gene, Discovered by Regeneron could be Game-Changer for NASH

  Regeneron and partner Alnylam have developed a siRNA therapeutic candidate targeting CIDEB gene that the companies anticipate will enter the clinic within the next year.

  August 3, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Business

  Roche Grasps at Alzheimer’s and Goes Big on Blood Cancers with Poseida

  Roche signed a big $6 billion-plus collaboration deal with Poseida on blood cancers while its partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.

  August 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  As Healthcare Crises Pile Up, Pharma Struggles to Meet Demand - Updated

  As the world faces one public health crisis after another, it seems that pharmaceutical companies across the board are having trouble keeping up with the ever-growing need for medicines.

  August 3, 2022

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Job Trends

  BioSpace Layoff Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and More Cull Staff

  The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.

  August 3, 2022

   · 

  12 min read

   · 

  Rosemary Scott
• 

  Policy

  Drug Pricing Debates Heat Up Just in Time for Election Season

  The debate over drug pricing tends to heat up during election season. With the mid-terms in November, we’re going through the cycle once again, sparked by provisions in the Inflation Reduction Act.

  August 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Regeneron’s Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales

  The real positive drivers were Eylea and Dupixent. Eylea climbed 14% to $1.62 billion, while Dupixent sales jumped almost 40% to $2.09 billion for the second quarter.

  August 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Diverse Patient Pools, Access Needed in Sickle Cell, Kidney Disease and Cancer

  Dr. Amaka Eneanya told BioSpace that kidney disease, which disproportionately affects people of color, has historically been underrepresented in clinical research compared to other areas of medicine.

  August 3, 2022

   · 

  5 min read

   · 

  Christie Adams